Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors

Macrophage infiltration has been identified as an independent poor prognostic factor for several cancers. Macrophages also orchestrate various tumor-promoting processes. This observation sparked an interest to therapeutically target these plastic innate immune cells. To date, blockade of colony-stim...

Full description

Saved in:
Bibliographic Details
Published inJournal of Immunotherapy and Precision Oncology Vol. 4; no. 2; pp. 105 - 114
Main Author Lin, Chia-Chi
Format Journal Article
LanguageEnglish
Published United States Innovative Healthcare Institute 01.05.2021
Subjects
colony-stimulating factor 1 receptor
Reviews
tenosynovial giant cell tumor
tumor-associated macrophages
colony-stimulating factor 1 receptor
tenosynovial giant cell tumor
tumor-associated macrophages
Online AccessGet full text

Cover

More Information
Summary:Macrophage infiltration has been identified as an independent poor prognostic factor for several cancers. Macrophages also orchestrate various tumor-promoting processes. This observation sparked an interest to therapeutically target these plastic innate immune cells. To date, blockade of colony-stimulating factor 1 (CSF1) or its receptor represents one of the selective approaches to manipulate tumor-associated macrophages. In this review, I discuss the efficacy and safety of various CSF1 receptor tyrosine kinase inhibitors, anti-CSF1 receptor monoclonal antibodies, and anti-CSF1 monoclonal antibodies in clinical development for patients with cancer and highlight potential combination partners, mainly anti-program cell death protein 1 (PD-1) and program cell death protein ligand 1 (PD-L1) antibodies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2666-2345
2590-017X
DOI:10.36401/JIPO-20-32